RHO and breast cancer: Using Rho inhibitor ZOL and LIMK inhibitor BMS3, our data further confirmed that FMNL2 suppressed breast cancer cell migration and invasion by inhibiting RhoA/LIMK/Cofilin pathway through a reduction of cytoplasmic p27 (Fig. 5H).